Maharashtra Herald

Glioma Market

DelveInsight’s “Glioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Glioma, historical and forecasted epidemiology as well as the Glioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Glioma market report provides current treatment practices, emerging drugs, Glioma market share of the individual therapies, and current and forecasted Glioma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Glioma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Glioma market.

Some of the key facts of the Glioma Market:

• The total incident population of low-grade glioma (LGG) in the 7 major markets was found to be 9,078 cases in 2021 and are projected to increase during the forecast period. 
• The total incident population of glioma in the United States is 3,654 in 2021. The United States contributed to the largest incident population of LGG, accounting for ~ 40% of the 7MM in 2021. 
• Among the EU5 countries, Germany accounted for the highest number of high-grade glioma cases, followed by France, whereas Spain accounted for the lowest cases in 2021. 

Got queries? Click here to know more about the Glioma Market Landscape

Glioma Overview

A glioma is a tumor of the central nervous system that arises from the glial stem or progenitor cells. Glial cells are a type of cell widely present in the nervous system. Gliomas mostly occur in the brain and, rarely, in the spinal cord. Classification of gliomas is complex and based partly on the microscopic appearance of the tumor (histologic classification) and partly on the gene changes (mutations) that are implicated in tumor development. Differentiation is an important concept for the histologic classification of gliomas and refers to the “specialization” of the cell.

Gliomas can have four different grades of differentiation. Grade 1 gliomas show the highest level of differentiation and are the least malignant, while grade 4 tumors are the least differentiated and most malignant. Loss of differentiation is known as anaplasia, hence the name of several grade 3 gliomas. Grade 1 and grade 2 gliomas are often referred to as low-grade gliomas, while grade 3 and 4 are referred to as malignant gliomas. 

Further classification is possible depending on the genetic alterations that occurred in the affected cells.

Gliomas are caused by the accumulation of genetic mutations in the glial stem or progenitor cells, leading to their uncontrolled growth. Mutated genes are typically involved in functions such as tumor suppression, DNA repair, and regulation of cell growth. A diagnosis of glioma requires an extensive patient history, as well as a complete physical and neurological examination. The presence of a brain tumor can be suspected with medical imaging. Magnetic resonance imaging (MRI) is the imaging modality of choice for the initial evaluation of glioma. The final diagnosis, and therefore plan for treatment, can only be determined after a piece of tumor tissue is analyzed microscopically. Further characterization can be done by testing the DNA of the affected cells to determine if mutations in genes associated with certain subtypes of glioma are present.

Glioma Epidemiology Insights:

• Based on GLOBOCAN 2020 estimates, 308,102 new cases of brain and central nervous system tumors were reported worldwide in 2020, with a higher prevalence in developed countries 
• As per the American Brain Tumor Association, more than 79,000 new cases of brain tumors are diagnosed each year; but only about 23,880 of these are malignant (cancerous) tumors or high-grade glioma of the brain or spinal cord. Gliomas overall make up about 74% of malignant brain tumors, wherein men are at a slightly higher risk, and the incidence of malignant brain tumors is low. In addition, anaplastic astrocytomas occur more often in younger adults ages 30–50, accounting for 17% of primary malignant brain tumors. Only 9% of childhood brain tumors are GBMs. 
• In a study by Greuter et al. (2021), approximately three quarters (74%) of all LGGs in children are WHO grade I, and 26% are Grade II. In adults, it is the opposite, with 85–90% of adult LGG being WHO grade II and 10–15% being WHO grade II. In children, most LGGs are pilocytic astrocytoma (65%), and diffuse LGG (60%) is more common in adults. For the forecasting purpose the contribution of Grade I and II is estimated from the CBTRUS data report 2021. 

Glioma Epidemiology Segmentation

• Total Glioma Incident Population
• Total Glioma grade specific incident population
• Total Glioma type specific population
• Total Glioma molecular alterations

Glioma Market Outlook 

The Glioma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Glioma market trends by analyzing the impact of current Glioma therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. This segment gives a thorough detail of the Glioma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Glioma market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Glioma market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Glioma Market

Glioma Key Companies 

• Orbus Therapeutics
• VBL Therapeutics 
• Candle Therapeutics
• Bayer
• And many more

 Glioma  Therapies

• Eflornithine
• Ofranergene obadenovec
• CAN-2409,
• CAN-3110
• And many more

 Table of Contents

• Key Insights 
• Report Introduction 
• Executive Summary of Glioma 
• Disease Background and Overview
• Epidemiology and patient population
• The United States 
• EU 5
• Glioma   Emerging Therapies
• Glioma Market Outlook
• Market Access and Reimbursement of Therapies
• Market Drivers 
• Market Barriers 
• Appendix
• Glioma Report Methodology
• DelveInsight Capabilities
• Disclaimer

Click here to read more about the Glioma Market research report

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/